New treatments in early age-related macular degeneration
5 September 2012
Volume 13, Issue 3
This article reviews the various treatment options available as prophylactic therapy for early AMD.
Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness amongst the elderly in the western world. An estimated 30% of people aged 75 years or older show at least the early manifestations of AMD, which consists of yellow deposits (drusen) and/or pigment clumps. In the UK, there are 25 000 new cases of wet AMD each year and the current intravitreal anti-VEGF therapy costs 1% of the annual £9 billion NHS budget. Currently, there is no treatment to prevent progression of the earlier stages of AMD. Prevention is better than cure and there is ongoing research into finding a preventive therapy for this disease. This article reviews the various treatment options available as prophylactic therapy for early AMD.
Sign in to view the article
Not a member? Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
Related further reading
The clinical figures that count.
A glance at what’s happening in the world of technology.
Increasing pressures on the NHS and patient-focused management mean interest in home monitoring of eye conditions has increased. Sophie Goodchild examines self-monitoring for wet AMD, the latest technology and what the future holds.